Lung Transplantation for Pleuroparenchymal Fibroelastosis
- Conditions
- Fibroelastosis
- Interventions
- Procedure: Lung transplantation (single, lobar or bilateral lung transplantation)
- Registration Number
- NCT05044390
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
This retrospective observational study will evaluate the outcomes of lung transplantation for a rare cause of interstitial lung disease called pleuroparenchymal fibroelastosis. Data will be collected from all transplantation center in France.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Lung transplantation (any type) for pleuroparenchymal fibroelastosis
- Histologically confirmed pleuroparenchymal fibroelastosis on the recipient lungs
Read More
Exclusion Criteria
- All other interstitial lung disease than pleuroparenchymal fibroelastosis
- Pleuroparenchymal fibroelastosis who didn't underwent lung transplantation
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description lung transplantation Lung transplantation (single, lobar or bilateral lung transplantation) Lung transplantation performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis.
- Primary Outcome Measures
Name Time Method Post-operative mortality Any death up to 90 days after lung transplantation Any death after lung transplantation during the first 30 days or during the hospitalization following the lung transplantation (in-hospital mortality)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
Bichat Claude Bernard Hospital, APHP
🇫🇷Paris, France
Foch Hospital
🇫🇷Suresnes, France
Marie Lannelongue Hospital
🇫🇷Le Plessis-Robinson, France
Hopital Louis Pradel
🇫🇷Lyon, France